CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

This is a phase II study of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide and
prednisone)induction chemotherapy followed by autologous stem cell transplant using
gemcitabine/busulfan/melphalan conditioning in patients with newly diagnosed systemic T-cell
non-Hodgkin lymphoma. The study treatment comprises 6 cycles of CHOEP, followed (for
responding patients) by stem cell mobilization and harvesting (using neupogen +/-
plerixafor) followed by high dose therapy and autologous stem cell transplantation,

Inclusion Criteria:

- Diagnosis of T-Cell lymphoma with mandatory pathologic review at Brigham and Women's
Hospital or Massachusetts General Hospital

- Measurable disease

- Candidate for Autologous Stem Cell Transplant

Exclusion Criteria:

- Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation,
one prior cycle of CHOP or up to 2 prior cycles of CHOEP)

- Pregnant or breastfeeding

- Alk-positive ACL

- Significant neuropathy precluding vincristine administration

- Known hypersensitivity to any of the agents used in the treatment

- Uncontrolled intercurrent illness

- Receiving other investigational agents

- History of a different malignancy except if disease free for at least 5 years or have
cervical cancer in situ or basal cell/squamous cell carcinoma of the skin

- HIV positive on anti-retroviral therapy